Il Dong Pharmaceutical Co Ltd
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-cancer, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central n… Read more
Il Dong Pharmaceutical Co Ltd (249420) - Total Liabilities
Latest total liabilities as of September 2025: ₩347.04 Billion KRW
Based on the latest financial reports, Il Dong Pharmaceutical Co Ltd (249420) has total liabilities worth ₩347.04 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Il Dong Pharmaceutical Co Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Il Dong Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Il Dong Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Il Dong Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Columbus McKinnon Corporation
NASDAQ:CMCO
|
USA | $839.67 Million |
|
Global Industrial Co
NYSE:GIC
|
USA | $286.50 Million |
|
Inner Mongolia North Hauler Joint Stock Co Ltd
SHG:600262
|
China | CN¥3.27 Billion |
|
Beijing Comens New Materials
SHE:300200
|
China | CN¥767.80 Million |
|
Kelly Services B Inc
NASDAQ:KELYB
|
USA | $1.27 Billion |
|
Carter Bank and Trust
NASDAQ:CARE
|
USA | $4.43 Billion |
|
Tanzanian Royalty Exploration Corp
NYSE MKT:TRX
|
USA | $76.66 Million |
|
Strike Energy Limited
OTCGREY:STKKF
|
USA | $130.16 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Il Dong Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Il Dong Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Il Dong Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual total liabilities of Il Dong Pharmaceutical Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩429.99 Billion | -1.60% |
| 2023-12-31 | ₩437.00 Billion | -4.50% |
| 2022-12-31 | ₩457.59 Billion | -16.56% |
| 2021-12-31 | ₩548.39 Billion | +56.36% |
| 2020-12-31 | ₩350.73 Billion | -2.53% |
| 2019-12-31 | ₩359.83 Billion | +25.01% |
| 2018-12-31 | ₩287.84 Billion | +2.97% |
| 2017-12-31 | ₩279.55 Billion | -0.85% |
| 2016-12-31 | ₩281.94 Billion | -- |